The comparison of Architect SCC and cobas SCC tests

Abstract

ntroduction: Squamous cell carcinoma antigen isolated by Kato and Torigoe in 1977, belonging to the serine and cysteine proteases inhibitors has been recognized as the marker of choice for the cervical cancer. However, high SCC expression has been also found in others neoplasms such as non-small cell lung cancer and head and neck carcinoma.<br>Material and Methods: For many years, for serum SCC-Ag determination the chemiluminescent microparticle immunoassay with the reference standard from Abbott Diagnostics has been used. Recently, also the electrochemiluminescence immunoassay produced by Roche Diagnostics is applied. This method has been standardized against the ARCHITECT SCC assay from Abbott Diagnostics.<br>Results: Significant correlations between the results of both analyzed tests were shown. The concentration of squamous cell antigen was tested using the ARCHITRCT SCC and COBAS SCC test in 109 patients with cervical cancer. The comparative analyses have revealed the higher COBAS SCC results in comparison with the ARCHITECT SCC assay across the all concentration range. The results obtained with the new COBAS SCC test were significantly higher than the previously used ARCHITECT SCC test.<br>Comments: The significant differences between SCC-Ag concentration of COBAS SCC and ARCHITECT SCC may be due to the different SCCA1 and SCCA2 properties of monoclonal antibodies.